Curie Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
35
About the Report
About the Report
Summary
Curie Institute is a cancer research foundation that operates cancer research institutes and hospitals and concentrates on the developing new treatments for cancer. The foundation carries out research in the areas of immunology, pharmachemistry, bioinformatics and systems biology, cell biology and developmental biology, among others. It provides services in the area such as genetics and carcinogenesis, cell and tissue imaging, and others. It offers care, research and training services for detecting, treating and monitoring cancer. Curie Institute provides services in anesthesia, medicine, pediatrics, surgery, tumor biology, intensive care, pain and medical imaging, among others. The foundation offers masters, PhD and postdoctoral fellowship programmes, and other courses. Curie Institute is headquartered in Paris, France.
Curie Institute-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Curie Institute, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Curie Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Curie Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Curie Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Curie Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Curie Institute, Medical Devices Deals, 2012 to YTD 2018 9
Curie Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Curie Institute, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Institut Curie Enters into Agreement with Pierre Fabre 12
Roche and Institut Curie Enter into Agreement 13
Institut Curie Enters into Collaboration Agreement with Epidemium 14
Ignyta and Institut Curie Enter into Partnership 15
Bristol-Myers Squibb Enters into Co-Development Agreement with Institut Curie 16
Celyad Enters into Partnership with Institut Curie 17
Curie-Cancer Extends Co-Development Agreement with GamaMabs Pharma 18
Curie-Cancer Partners with Inventiva 19
Institut Curie Extends Research Agreement with Servier 20
Curie-Cancer Enters into Co-Development Agreement with GamaMabs Pharma 21
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 22
Curie-Cancer And GenoSplice Form Bioinformatics Partnership For Cancer Genomics 23
Curie-Cancer Enters Into Research Agreement With Harmonic Pharma 24
Licensing Agreements 25
Stimunity Enters into Licensing Agreement with Inserm Transfert and Institut Curie 25
Theravectys Enters into Licensing Agreement with Institut Curie 26
Abbott Molecular Enters into Licensing Agreement with Institut Curie 27
PEP-Therapy Enters into Agreement with Inserm Transfert, Institut Curie and Pierre and Marie 28
Meiogenix Enters Into Licensing Agreement With Curie-Cancer And Institut National de la Recherche Agronomique 29
Floralis Enters into Licensing Agreement with Ecrins Therapeutics 30
Curie Institute-Key Competitors 31
Curie Institute-Key Employees 32
Curie Institute-Locations And Subsidiaries 33
Head Office 33
Recent Developments 34
Strategy And Business Planning 34
Sep 17, 2018: Institut Curie announces creation of Honing Biosciences 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35
List of Figure
List of Figures
Curie Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Curie Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Curie Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Curie Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Curie Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Curie Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Curie Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Curie Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Curie Institute, Medical Devices Deals, 2012 to YTD 2018 9
List of Table
List of Tables
Curie Institute, Pharmaceuticals & Healthcare, Key Facts 2
Curie Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Curie Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Curie Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Curie Institute, Deals By Therapy Area, 2012 to YTD 2018 8
Curie Institute, Medical Devices Deals, 2012 to YTD 2018 9
Curie Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Institut Curie Enters into Agreement with Pierre Fabre 12
Roche and Institut Curie Enter into Agreement 13
Institut Curie Enters into Collaboration Agreement with Epidemium 14
Ignyta and Institut Curie Enter into Partnership 15
Bristol-Myers Squibb Enters into Co-Development Agreement with Institut Curie 16
Celyad Enters into Partnership with Institut Curie 17
Curie-Cancer Extends Co-Development Agreement with GamaMabs Pharma 18
Curie-Cancer Partners with Inventiva 19
Institut Curie Extends Research Agreement with Servier 20
Curie-Cancer Enters into Co-Development Agreement with GamaMabs Pharma 21
Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 22
Curie-Cancer And GenoSplice Form Bioinformatics Partnership For Cancer Genomics 23
Curie-Cancer Enters Into Research Agreement With Harmonic Pharma 24
Stimunity Enters into Licensing Agreement with Inserm Transfert and Institut Curie 25
Theravectys Enters into Licensing Agreement with Institut Curie 26
Abbott Molecular Enters into Licensing Agreement with Institut Curie 27
PEP-Therapy Enters into Agreement with Inserm Transfert, Institut Curie and Pierre and Marie 28
Meiogenix Enters Into Licensing Agreement With Curie-Cancer And Institut National de la Recherche Agronomique 29
Floralis Enters into Licensing Agreement with Ecrins Therapeutics 30
Curie Institute, Key Competitors 31
Curie Institute, Key Employees 32
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.